Viking Therapeutics (NASDAQ: VKTX), a biotech stock that has rocketed to prominence thanks to one of its investigational ...

I'm bullish on Viking Therapeutics' weight-loss drug, but warn of risks and competition ahead. Click here to read my most ...

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Viking ...

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $63.13, with a +1.94% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.19% ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

While it might not perfectly follow in the larger biotech's footsteps, TERN-601 has the potential to be one of the safer, ...

Two stocks at opposite ends of the spectrum are Amgen (NASDAQ: AMGN), the healthcare behemoth, and Viking Therapeutics ...

The general mood among these heavyweight investors is divided, with 57% leaning bullish and 26% bearish. Among these notable ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $70.47 which represents a slight increase of $2.31 or 3.39% from the prior close of $68.16. The stock opened at $69.5 and ...

That's the big thrill about owning Viking Therapeutics. If the company's GLP-1 treatment, referred to as just VK2735 for now, obtains approval, this already hot stock could become an even more ...